Jennifer B. D'Amico, SVP & Controller at Pfizer (PFE), has demonstrated a long-term net buying bias in company stock, with $1.93 million in total purchases against $1.68 million in sales across 33 transactions. Her activity has been exclusively concentrated in PFE shares, with no trades in other securities. The most recent filing on March 4, 2026, shows a sale valued at $21,988, continuing a pattern of smaller discretionary sales alongside larger equity award transactions. Earlier in February 2026, D'Amico acquired $593,812 worth of shares through market purchases on February 25, followed by a $449,214 open market buy the same day, representing her most substantial recent acquisitions.
The transaction history reveals a rhythm of annual equity activity, with notable purchases in late February—likely tied to vesting events—followed by smaller sales. For instance, on February 27, 2025, she acquired $701,845 in shares while selling $547,104 worth the same day, suggesting tax or portfolio rebalancing motives. The overall pattern shows consistent accumulation of PFE stock, with periodic monetization of awards. While her 2026 activity includes one sale so far, her position has grown substantially through both open market purchases (coded F) and equity awards (coded M), maintaining a clear buy-and-hold approach to Pfizer shares.
AI-assisted summary